Amylyx’s Relyvrio Could See Fast Sales Growth, But Also Spark Pricing Debate

Interpret Survival Analysis “Cautiously,” Label Advises

The FDA approved Amylyx's Relyvrio for amyotrophic lateral sclerosis • Source: Shutterstock

More from New Products

More from Scrip